Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases utilizing its proprietary technology platform. The company is recognized for its ability to provide rapid and precise testing, which enhances clinical decision-making and improves patient outcomes. With a strong commitment to ongoing research and development, Alamar is well-positioned to address pressing medical needs, making it an appealing investment opportunity for institutional investors looking to capitalize on growth within the expanding diagnostics market.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$29.95
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 10, 2026 | $-0.36 | $-0.22 | Beat +38.9% | $-0.22 | $25.9M | $29.4M | +13.5% | 1D Pre+1.3% | On-Day-1.7% | 1D Post+30.7% |
Q ended Mar 31, 2026 Reported May 8, 2026 | — | $-1.74 | — | $-1.74 | — | $26.0M | — | 1D Pre-0.8% | On-Day+1.3% | 1D Post-0.3% |
Q ended Mar 31, 2025 Report date n/a | — | |||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| — |
| — |
| $13.1M |
| — |
| 1D Pre— |
| On-Day— |
| 1D Post— |